NIT
OCUL icon

NumerixS Investment Technologies’s Ocular Therapeutix OCUL Stock Holding History

NumerixS Investment Technologies’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,300
Closed -$86K – 1283
2017
Q1 		$86K Sell
9,300
-25,900
-74% -$216K 0.01% 925
2016
Q4 		$295K Buy
+35,200
New +$273K 0.04% 554

Other funds holding OCUL

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NumerixS Investment Technologies's OCUL Position: Q2 2017 in Review

NumerixS Investment Technologies sold out of Ocular Therapeutix (OCUL) in Q2 2017, closing a stake of 9,300 shares — an estimated $86K sold.

NumerixS Investment Technologies first reported a position in OCUL in Q4 2016 and held it in 2 quarters. The position peaked at $295K in Q4 2016. 72 funds tracked by Wall St. Rank hold OCUL as of Q2 2017.

  • NumerixS Investment Technologies reported no remaining Ocular Therapeutix position as of Q2 2017 after selling out during the quarter.
  • NumerixS Investment Technologies sold 9,300 Ocular Therapeutix shares in Q2 2017, an estimated $86K.
  • NumerixS Investment Technologies first reported a position in Ocular Therapeutix in Q4 2016 and held it in 2 quarters.
  • NumerixS Investment Technologies's Ocular Therapeutix position peaked at $295K in Q4 2016.
  • 72 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2017.

Based on NumerixS Investment Technologies's 13F filing for Q2 2017, filed 9 Aug 2017.